Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

78.28 -2.68 (-3.31%)
Official Closing Price Updated: 7:00 PM EDT, Jun 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,052,114
Open 80.28
Bid (Size) 77.92 (1)
Ask (Size) 78.50 (10)
Prev. Close 80.96
Today's Range 78.19 - 80.70
52wk Range 73.31 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 4.14%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
Exposures Political
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones index could have fared better in May if not for these two stocks. 
Via The Motley Fool
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal

Performance

YTD
-21.1%
-21.1%
1 Month
+1.4%
+1.4%
3 Month
-17.4%
-17.4%
6 Month
-21.8%
-21.8%
1 Year
-38.6%
-38.6%

More News

Read More
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
Via Benzinga
Exposures Product Safety
Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish
Via Stocktwits
Topics Death
Exposures Death Product Safety
Price Over Earnings Overview: Merck & Co
Via Benzinga
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
From Merck & Co., Inc.
Via Business Wire
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
From Merck & Co., Inc.
Via Business Wire
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Via The Motley Fool
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals
Via Chartmill
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
Via Benzinga
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish
Via Stocktwits
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Top S&P500 movers in Monday's pre-market session
Via Chartmill
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
From Merck & Co., Inc.
Via Business Wire
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Economy Stocks
Exposures Interest Rates US Equities
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Via Benzinga

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 78.28
When was Merck & Co last traded?
The last trade of Merck & Co was at 06/17/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 198.16B
How many shares of Merck & Co are outstanding?
Merck & Co has 198B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.